Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: Possible use for assessment of a therapeutic regimen

Brain Research

Volumn 1133, Issue 1, 2007, Pages 200-208

  Satoh, Hiroyuki ^a   Yamato, Osamu ^a   Asano, Tomoya ^a   Yonemura, Madoka ^a   Yamauchi, Toyofumi ^a   Hasegawa, Daisuke ^b   Orima, Hiromitsu ^b   Arai, Toshiro ^b   Yamasaki, Masahiro ^a   Maede, Yoshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Aspartate aminotransferase; Canine model; Cerebrospinal fluid biomarker; Glucocorticoid therapy; GM1 gangliosidosis; Lactate dehydrogenase

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; BIOLOGICAL MARKER; GANGLIOSIDE GM1; GLUCOCORTICOID; LACTATE DEHYDROGENASE; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; GM1 GANGLIOSIDOSIS; INFLAMMATION; LONG TERM CARE; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BRAIN; CEREBROSPINAL FLUID PROTEINS; DISEASE MODELS, ANIMAL; DOGS; G(M1) GANGLIOSIDE; GANGLIOSIDOSIS, GM1; L-LACTATE DEHYDROGENASE; MYELIN BASIC PROTEINS; NERVE DEGENERATION; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; TREATMENT OUTCOME; UP-REGULATION;

CANIS FAMILIARIS;

EID: 33846280791     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.11.039     Document Type: Article

References (48)

1. Aronson S.M., Saifer A., Perle G., and Volk B.W. Cerebrospinal fluid enzymes in central nervous system lipidoses (with particular reference to amaurotic family idiocy). Proc. Soc. Exp. Biol. Med. 97 (1958) 331-334
2. Asano N., Ishii S., Kizu H., Ikeda K., Yasuda K., Kato A., Martin O.R., and Fan J.Q. In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem. 267 (2000) 4179-4186
3. 2 forming NADPH oxidase in microglia, monocytes, and neutrophils - a possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 274 (1999) 15493-15499
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Esmonde T. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet 351 (1998) 63
6. Fan J.Q., Ishii S., Asano N., and Suzuki Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 5 (1999) 112-115
7. Folch J., Lees M., and Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
8. Folkerth R.D. Abnormalities of developing white matter in lysosomal storage diseases. J. Neuropathol. Exp. Neurol. 58 (1999) 887-902
9. Gehrmann J., Matsumoto Y., and Kreutzberg G.W. Microglia: intrinsic immune effector cell of the brain. Brain Res. Brain Res. Rev. 20 (1995) 269-287
10. Hahn C.N., del Pilar Martin M., Schröder M., Vanier M.T., Hara Y., Suzuki K., Suzuki K., and d'Azzo A. Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid β-galactosidase. Hum. Mol. Genet. 6 (1997) 205-211
11. Hatfield R.H., and McKernan R.M. CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res. 577 (1992) 249-252
12. Huang J.Q., Trasler J.M., Igdoura S., Michaud J., Hanai N., and Gravel R.A. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 6 (1997) 1879-1885
13. Ichinomiya, S., Watanabe, H., Maruyama, K., Toda, H., Iwasaki, H., Kurosawa, M., Matsuda, J., Suzuki, Y., in press. Motor and reflex testing in GM1-gangliosidosis model mice. Brain Dev.
14. Izumi T., Ogawa T., Koizumi H., and Fukuyama Y. Normal developmental profiles of CSF gangliotetraose-series gangliosides from neonatal period to adolescence. Pediatr. Neurol. 9 (1993) 297-300
15. Jeyakumar M., Thomas R., Elliot-Smith E., Smith D.A., van der Spoel A.C., d'Azzo A., Hugh Perry V., Butters T.D., Dwek R.A., and Platt F.M. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126 (2003) 974-987
16. Jeyakumar M., Smith D.A., Williams I.M., Borja M.C., Neville D.C.A., Butters T.D., Dwek R.A., and Platt F.M. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol. 56 (2004) 642-649
17. Jourdian G.W., Dean L., and Roseman S. The sialic acids: XI. A periodate-resorcinol method for the quantitative estimation of free sialic acids and their glycosides. J. Biol. Chem. 246 (1971) 430-435
18. Kaye E.M., Ullman M.D., Kolodny E.H., Krivit W., and Rischert J.C. Possible use of CSF glycosphingolipids for the diagnosis and therapeutic monitoring of lysosomal storage diseases. Neurology 42 (1992) 2290-2294
19. Lassmann H., Bancher C., Breitschopf H., Wegiel J., Bobinski M., Jellinger K., and Wisniewski H.M. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 89 (1995) 35-41
20. Matsuda J., Suzuki O., Oshima A., Ogura A., Naiki M., and Suzuki Y. Neurological manifestations of knockout mice with β-galactosidase deficiency. Brain Dev. 19 (1997) 19-20
21. Matsuda J., Suzuki O., Oshima A., Yamamoto Y., Noguchi A., Takimoto K., Itoh M., Matsuzaki Y., Yasuda Y., Ogawa S., Sakata Y., Nanba E., Higaki K., Ogawa Y., Tominaga L., Ohno K., Iwasaki H., Watanabe H., Brady R.O., and Suzuki Y. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15912-15917
22. Myerowitz R., Lawson D., Mizukami H., Mi Y., Tifft C.J., and Proia R.L. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. 11 (2002) 1343-1350
23. O'Neill K., Chen S., and Diaz Brinton R. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp. Neurol. 188 (2004) 268-278
24. Orlino Jr. E.N., Olmstead C.E., Lazareff J.A., Peacock W.J., Fisher R.S., and Fluharty A.L. An enzyme immunoassay for neuron-specific enolase in cerebrospinal fluid. Biochem. Mol. Med. 61 (1997) 41-46
25. Osuna E., Perez-Carceles M.D., Luna A., and Pounder D.J. Efficacy of cerebro-spinal fluid biochemistry in the diagnosis of brain insult. Forensic Sci. Int. 52 (1992) 193-198
26. Parakh N., Gupta H.L., and Jain A. Evaluation of enzymes in serum and cerebrospinal fluid in cases of stroke. Neurol. India 50 (2002) 518-519
27. Riemenschneider M., Buch K., Schmolke M., Kurz A., and Guder W.G. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet 350 (1997) 784
28. Satoh H., Yamato O., Asano T., Yamasaki M., and Maede Y. Increased concentration of GM1-ganglioside in cerebrospinal fluid in dogs with GM1- and GM2-gangliosidoses and its clinical application for diagnosis. J. Vet. Diagn. Invest. 16 (2004) 223-226
29. Schiffmann R., and Brady R.O. New prospects for the treatment of lysosomal storage diseases. Drugs 62 (2002) 733-742
30. Schmidt H., Otto M., Niedmann P., Cepek L., Schröter A., Kretzschmar H.A., and Poser S. CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias. Dementia Geriatr. Cognit. Disord. 17 (2004) 204-206
31. Su J.H., Anderson A.J., Cummings B.J., and Cotman C.W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5 (1994) 2529-2533
32. Suzuki Y., Oshima A., and Nanba E. β-Galactosidase deficiency (β-galactosidosis): GM1 gangliosidosis and Morquio B disease. In: Scriver C.R., Beaudet A.L., Valle D., Sly W.S., Childs B., Kinzler K.W., and Vogelstein B. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3775-3809
33. Tapiola T., Lehtovirta M., Pirttilä T., Alafuzoff I., Riekkinen P., and Soininen H. Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease. Lancet 352 (1998) 287
34. Tessitore A., del Pilar Martin M., Sano R., Ma Y., Mann L., Ingrassia A., Laywell E.D., Steindler D.A., Hendershot L.M., and d'Azzo A. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15 (2004) 753-766
35. van der Voorn J.P., Kamphorst W., van der Knaap M.S., and Powers J.M. The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction. Acta Neuropathol. (Berl.) 107 (2004) 539-545
36. Wada R., Tifft C.J., and Proia R.L. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10954-10959
37. Williams M.A., and McCluer R.H. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J. Neurochem. 35 (1980) 266-269
38. Wu Y.P., and Proia R.L. Deletion of macrophage-inflammatory protein 1α retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8425-8430
39. Yamaguchi A., Katsuyama K., Nagahama K., Takai T., Aoki I., and Yamanaka S. Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses. J. Clin. Invest. 113 (2004) 200-208
40. Yamanaka T., Hirabayashi Y., Koketsu K., Higashi H., and Matsumoto M. Highly sensitive analysis of gangliosides in human cerebrospinal fluid with neurological diseases. Jpn. J. Exp. Med. 57 (1987) 131-135
41. Yamato O., Ochiai K., Masuoka Y., Hayashida E., Tajima M., Omae S., IIjima M., Umemura T., and Maede Y. GM1 gangliosidosis in Shiba dogs. Vet. Rec. 146 (2000) 493-496
42. Yamato O., Endoh D., Kobayashi A., Masuoka Y., Yonemura M., Hatakeyama A., Satoh H., Tajima M., Yamasaki M., and Maede Y. A novel mutation in the gene for canine acid β-galactosidase that causes GM1-gangliosidosis in Shiba dogs. J. Inherited Metab. Dis. 25 (2002) 525-526
43. Yamato O., Matsuki N., Satoh H., Inaba M., Ono K., Yamasaki M., and Maede Y. Sandhoff disease in a golden retriever dog. J. Inherited Metab. Dis. 25 (2002) 319-320
44. Yamato O., Masuoka Y., Yonemura M., Hatakeyama A., Kobayashi A., Satoh H., Nakayama M., Ochiai K., Umemura T., and Maede Y. Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid β-galactosidase: a canine model of human GM1-gangliosidosis. J. Vet. Med. Sci. 65 (2003) 213-217
45. Yamato O., Jo E.O., Shoda T., Yamasaki M., and Maede Y. Rapid and simple mutation screening of GM1-gangliosidosis in Shiba dogs by direct amplification of deoxyribonucleic acid from various forms of canine whole-blood specimens. J. Vet. Diagn. Invest. 16 (2004) 469-472
46. Yamato O., Kobayashi A., Satoh H., Endoh D., Shoda T., Masuoka Y., Hatakeyama A., Jo E.O., Asano T., Yonemura M., Yamasaki M., and Maede Y. Comparison of polymerase chain reaction-restriction fragment length polymorphism assay and enzyme assay for diagnosis of GM1-gangliosidosis in Shiba dogs. J. Vet. Diagn. Invest. 16 (2004) 299-304
47. Yamato O., Matsunaga S., Takata K., Uetsuka K., Satoh H., Shoda T., Baba Y., Yasoshima A., Kato K., Takahashi K., Yamasaki M., Nakayama H., Doi K., Maede Y., and Ogawa H. GM2-gangliosidosis variant 0 (Sandhoff-like disease) in a family of Japanese domestic cats. Vet. Rec. 155 (2004) 739-744
48. Yamato O., Satoh H., Matsuki N., Ono K., Yamasaki M., and Maede Y. Laboratory diagnosis of canine GM2-gangliosidosis using blood and cerebrospinal fluid. J. Vet. Diagn. Invest. 16 (2004) 39-44